List of Excipients in Branded Drug TRUSOPT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	TRUSOPT	dorzolamide hydrochloride	0006-3519	BENZALKONIUM CHLORIDE
Merck Sharp & Dohme LLC	TRUSOPT	dorzolamide hydrochloride	0006-3519	HYDROXYETHYL CELLULOSE
Merck Sharp & Dohme LLC	TRUSOPT	dorzolamide hydrochloride	0006-3519	MANNITOL
Merck Sharp & Dohme LLC	TRUSOPT	dorzolamide hydrochloride	0006-3519	SODIUM HYDROXIDE
Merck Sharp & Dohme LLC	TRUSOPT	dorzolamide hydrochloride	0006-3519	TRISODIUM CITRATE DIHYDRATE
Merck Sharp & Dohme LLC	TRUSOPT	dorzolamide hydrochloride	0006-3519	WATER

TRUSOPT Excipient Strategy and Commercial Opportunities in Dorzolamide Ophthalmic Solutions

Last updated: October 25, 2026

TRUSOPT is a 2% dorzolamide hydrochloride ophthalmic solution for reducing elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Its commercial value is no longer protected by primary small-molecule exclusivity. Opportunity has shifted to preservative-free delivery, multidose packaging, tolerability, supply reliability, combination products, and differentiated ophthalmic formulations.

What is TRUSOPT and how does its formulation work?

TRUSOPT contains dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. The product reduces aqueous humor production and lowers intraocular pressure. The marketed concentration is 2% dorzolamide, equivalent to approximately 2.3% dorzolamide hydrochloride.

The original TRUSOPT formulation uses a buffered aqueous vehicle designed to maintain dorzolamide solubility and ophthalmic tolerability.

Product attribute	TRUSOPT profile
Active ingredient	Dorzolamide hydrochloride
Strength	2% dorzolamide
Dosage form	Sterile ophthalmic solution
Primary indication	Ocular hypertension and open-angle glaucoma
Administration	Typically one drop three times daily as monotherapy
Original sponsor	Merck & Co.
Route	Topical ophthalmic
Preservative in multidose product	Benzalkonium chloride
Prescription status	FDA-approved prescription drug
Reference product pathway	NDA 020408

The formulation relies on a combination of pH control, tonicity adjustment, viscosity management, and antimicrobial preservation. Dorzolamide is an ionizable compound, so pH and buffer selection affect solubility, comfort, chemical stability, and container compatibility.

What excipients are used in TRUSOPT?

The standard multidose TRUSOPT formulation contains benzalkonium chloride, hydroxyethyl cellulose, mannitol, sodium citrate dihydrate, sodium hydroxide, and purified water. The active pharmaceutical ingredient is dorzolamide hydrochloride.

Excipient	Functional role	Commercial relevance
Benzalkonium chloride	Antimicrobial preservative	Supports multidose packaging but may create ocular-surface tolerability concerns
Hydroxyethyl cellulose	Viscosity modifier	Increases residence time and can improve drop retention
Mannitol	Tonicity agent and formulation stabilizer	Helps adjust osmolality without relying only on sodium chloride
Sodium citrate dihydrate	Buffer component	Supports pH control and dorzolamide solution stability
Sodium hydroxide	pH adjustment	Establishes the target formulation pH
Purified water	Solvent	Main vehicle for the ophthalmic solution

The product label identifies a pH of approximately 5.6. The formulation is manufactured as a sterile solution and packaged in a multidose ophthalmic container (Merck Sharp & Dohme, 2024).

Why benzalkonium chloride matters commercially

Benzalkonium chloride, commonly abbreviated BAK, is effective at controlling microbial contamination in multidose ophthalmic products. Its use also creates a product-differentiation opportunity. Chronic glaucoma treatment requires long-term administration, and repeated exposure to BAK has been associated with ocular-surface irritation and tear-film effects in some patients.

A dorzolamide product that removes BAK while preserving chemical stability and sterility can target:

• Patients with dry eye or ocular-surface disease.
• Patients receiving several chronic ophthalmic medicines.
• Patients who experience burning or irritation with preserved products.
• Ophthalmologists seeking preservative-free therapy for long-term use.
• Health systems with protocols favoring preservative-free glaucoma products.

The commercial challenge is that preservative removal increases packaging, sterility, and manufacturing costs. A preservative-free formulation must control microbial risk through single-dose packaging, validated container closure, aseptic processing, or a proprietary multidose system.

What is the difference between TRUSOPT and preservative-free dorzolamide?

TRUSOPT is associated with a conventional preserved multidose solution, while TRUSOPT PF and generic preservative-free dorzolamide products use packaging and manufacturing controls that eliminate or reduce dependence on BAK.

Attribute	Preserved dorzolamide solution	Preservative-free dorzolamide solution
Antimicrobial strategy	Chemical preservative	Single-dose container, aseptic control, or specialized multidose device
Primary excipient issue	BAK exposure	Higher packaging and manufacturing complexity
Likely patient target	Broad glaucoma population	Ocular-surface-sensitive and chronic-use patients
Cost structure	Lower unit packaging cost	Higher container and filling cost
Differentiation	Limited after generic entry	Meaningful if tolerability and usability improve
Regulatory burden	Conventional ophthalmic solution	Sterility, container closure, and dose-delivery evidence are central

Preservative-free dorzolamide is commercially attractive because the active ingredient is mature and widely available. The value proposition must therefore come from patient tolerability, adherence, packaging convenience, reduced waste, or payer acceptance.

What formulation patents protect TRUSOPT?

The original dorzolamide intellectual-property estate covered the active compound and ophthalmic compositions. The principal U.S. compound patent historically associated with dorzolamide was U.S. Patent No. 4,797,413, assigned to Merck. That patent expired after the standard U.S. patent term applicable to its filing date.

The original compound and formulation patents do not provide current broad exclusivity for conventional dorzolamide ophthalmic solutions. Current commercial protection is more likely to arise from:

• Product-specific formulation patents.
• Preservative-free compositions.
• Container and closure systems.
• Multidose dispensing devices.
• Manufacturing methods.
• Combination products containing dorzolamide and another glaucoma agent.
• Method-of-use claims covering dosing or treatment subgroups.

Patent scope must be assessed claim by claim. A formulation patent may protect a narrow pH range, excipient combination, concentration, container, or stability profile without blocking all dorzolamide products.

What is the Orange Book status of TRUSOPT?

TRUSOPT is an FDA-approved reference product, but the original compound exclusivity has expired. Generic dorzolamide ophthalmic solutions have entered the U.S. market through abbreviated new drug applications.

The commercial consequences are material:

1. Conventional dorzolamide solution is exposed to generic competition.
2. A generic applicant can generally rely on the reference product’s safety and efficacy findings.
3. Paragraph IV disputes are less important for expired foundational patents than for later-listed product or formulation patents.
4. New intellectual property must be sufficiently narrow and non-obvious to withstand invalidity and non-infringement challenges.
5. A preservative-free or device-based product may require separate regulatory and patent analysis.

The FDA Orange Book should be reviewed for current listed patents, exclusivity codes, and reference-product status before evaluating a launch or licensing transaction. Historical patents associated with TRUSOPT should not be treated as active barriers without confirming their expiration, terminal disclaimers, pediatric extensions, and any later-listed patents (U.S. Food and Drug Administration, 2024a).

When did TRUSOPT lose exclusivity?

TRUSOPT lost meaningful market exclusivity after expiration of the principal dorzolamide patent estate and the availability of generic dorzolamide products. The product is now a mature ophthalmic asset rather than a conventional protected-brand opportunity.

The relevant commercial timeline is:

Period	Commercial event
1990s	FDA approval and initial commercialization of TRUSOPT
Late 1990s	Expansion of dorzolamide use in glaucoma treatment
Patent expiry period	Loss of foundational compound and composition protection
Post-expiry period	Entry of generic dorzolamide ophthalmic solutions
Current market	Competition based on price, supply, preservation, packaging, and tolerability

FDA exclusivity and patent protection are separate. Regulatory exclusivity may expire before or after patent rights, and neither should be inferred solely from the product launch date.

What commercial opportunities exist for dorzolamide excipients?

The strongest opportunity is not a simple reformulation of TRUSOPT. It is a differentiated delivery platform that solves a recognized problem in chronic ophthalmic treatment.

Preservative-free dorzolamide

A preservative-free product can command a price premium if it demonstrates better ocular-surface tolerability or supports use in patients who cannot tolerate BAK. The product must address unit-dose handling, sterility assurance, dosing accuracy, and packaging waste.

Low-preservative or alternative-preservative systems

Alternative antimicrobial systems could reduce BAK exposure while retaining multidose convenience. Candidate approaches include oxidative preservative systems, stabilized oxychloro complexes, or other ophthalmically accepted preservation technologies. Each candidate requires compatibility testing with dorzolamide, the buffer system, elastomeric components, and the bottle.

The principal risks are degradation, comfort, preservative depletion, microbial challenge-test performance, and regulatory acceptability.

Viscosity and residence-time optimization

Hydroxyethyl cellulose already provides modest viscosity control. A more advanced rheology strategy could increase ocular residence time and reduce drainage without causing blurred vision or excessive dosing discomfort.

Potential commercial benefits include:

• Lower dosing frequency.
• Improved patient adherence.
• Reduced systemic drainage.
• Lower daily medication burden.
• Product differentiation against low-cost generic solutions.

A higher-viscosity product must demonstrate acceptable drop size, ease of administration, sterility, clarity, and compatibility with common ophthalmic containers.

Fixed-dose combinations

Dorzolamide is already used in combination with timolol, including the COSOPT product family. Combination opportunities include dorzolamide with prostaglandin analogues, alpha agonists, or other glaucoma agents.

The commercial rationale is straightforward: one bottle can reduce administration complexity. The development risks include chemical compatibility, pH compromise between active ingredients, preservative burden, dosing equivalence, and the need to establish combination-product regulatory support.

Device-enabled products

A specialized multidose bottle can provide preservative-free or low-preservative delivery while improving dose control. Device patents may cover:

• One-way valves.
• Airless dispensing.
• Microbial barrier systems.
• Metered-dose pumps.
• Low-dead-volume containers.
• Position-independent dispensing.
• Child-resistant packaging.

Device differentiation can be more defensible than a minor excipient change, but the product becomes a drug-device combination with greater development and manufacturing complexity.

How strong is the TRUSOPT patent estate today?

The original TRUSOPT estate is weak as a broad barrier to conventional dorzolamide solutions because the foundational patents have expired and generic products are established. New patent strength depends on claim quality rather than the historical importance of the TRUSOPT brand.

Patent category	Current strategic strength
Original dorzolamide compound patent	Expired
Conventional dorzolamide solution	Low protection
BAK-free composition	Moderate if technically narrow and clinically differentiated
Multidose preservative-free device	Moderate to strong if claims cover validated architecture
Fixed-dose combination	Product-dependent
Manufacturing process	Moderate if process produces a measurable quality advantage
Method of use	Usually limited unless tied to a defined patient group or dosing regimen

The most defensible strategy combines composition claims, container claims, process claims, and clinical-use claims. A single narrow excipient claim is vulnerable to design-around.

Which companies are challenging or competing with TRUSOPT?

The competitive field includes generic manufacturers selling dorzolamide ophthalmic solution and companies marketing alternative glaucoma therapies. Competition comes from:

• Generic dorzolamide solution.
• Dorzolamide-timolol fixed combinations.
• Brimonidine products.
• Prostaglandin analogues such as latanoprost, bimatoprost, and travoprost.
• Preservative-free glaucoma products.
• Sustained-release and implantable delivery systems.

Generic manufacturers compete primarily on price and supply. Branded and specialty ophthalmology companies compete through tolerability, dosing frequency, preservative-free packaging, adherence, and physician preference.

What generic launch risks exist for a new dorzolamide product?

A new product faces four principal risks.

First, the active ingredient is commoditized. A formulation must demonstrate value beyond equivalent dorzolamide concentration.

Second, excipient changes can affect bioavailability at the ocular surface, local tolerability, pH, osmolality, viscosity, and drop volume.

Third, ophthalmic manufacturing requires high sterility and container-closure performance. A low-cost formulation may fail commercial launch because of filling losses, particulate control, extractables, or microbial contamination.

Fourth, payers may place a differentiated product in the same reimbursement tier as generic dorzolamide unless the sponsor produces evidence supporting lower treatment burden or better persistence.

What revenue exposure does TRUSOPT have?

TRUSOPT’s direct revenue exposure is limited by generic substitution and the age of the product. The larger opportunity is the dorzolamide molecule as a platform for differentiated ophthalmic products.

Revenue potential is strongest in:

• Preservative-free products.
• Combination therapies.
• Specialty pharmacy or hospital channels.
• Markets with high chronic glaucoma prevalence.
• Products with improved dosing frequency.
• Contract manufacturing and private-label supply.
• Regional licensing of ophthalmic technology.

A conventional preserved generic solution is a volume business with low differentiation. A preservative-free, device-enabled product can support higher pricing but requires evidence of clinical and practical benefit.

Key Takeaways

• TRUSOPT is a 2% dorzolamide hydrochloride ophthalmic solution for glaucoma and ocular hypertension.
• Its core excipient system includes benzalkonium chloride, hydroxyethyl cellulose, mannitol, sodium citrate, sodium hydroxide, and water.
• The original patent estate no longer provides broad protection for conventional dorzolamide solutions.
• Preservative-free formulations offer the clearest excipient-led opportunity.
• Multidose preservative-free devices, fixed-dose combinations, and improved residence-time formulations have stronger commercial potential than simple excipient substitutions.
• Generic competition makes price-based differentiation difficult.
• Patent value is most likely to arise from integrated composition, packaging, manufacturing, and method-of-use claims.
• Regulatory review should focus on FDA Orange Book status, ANDA substitutability, sterility, preservative effectiveness, container closure, and formulation comparability.

FAQs

Is benzalkonium chloride required in every dorzolamide eye drop?

No. Benzalkonium chloride is used in conventional multidose products, but preservative-free dorzolamide products can use single-dose packaging, aseptic controls, or specialized multidose containers.

Can hydroxyethyl cellulose be replaced in a TRUSOPT-like formulation?

Yes, but the substitute must maintain acceptable viscosity, drop size, clarity, sterility, ocular comfort, and dorzolamide stability. A substitution can create a new formulation profile but does not automatically create meaningful patent protection.

Is preservative-free dorzolamide eligible for FDA approval as a generic?

Potentially. The regulatory pathway depends on the product design, reference-product relationship, dosage form, packaging system, and whether the formulation qualifies as pharmaceutically equivalent and bioequivalent under the applicable ANDA requirements.

Does a new dorzolamide excipient combination avoid all TRUSOPT patents?

No. Patent clearance requires review of active, expired, pending, and later-issued claims covering formulation, manufacturing, packaging, combinations, and methods of use.

Is dorzolamide-timolol a stronger commercial opportunity than TRUSOPT?

A fixed combination can have greater commercial value because it reduces dosing complexity, but it also faces established generic competition and greater formulation-complexity risk.

References

1. Merck Sharp & Dohme LLC. (2024). TRUSOPT (dorzolamide hydrochloride ophthalmic solution) prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Patent No. 4,797,413. (1989). Ophthalmic compositions containing carbonic anhydrase inhibitors. United States Patent and Trademark Office.

5. U.S. Food and Drug Administration. (2024c). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/